UPADACITINIB IN ADULT ATOPIC DERMATITIS: LOSS OF ITCH EFFICACY AFTER TREATMENT WITHDRAWAL IN A PHASE 2B TRIAL

被引：0
|
作者：
Staender, Sonja [1 ,2 ]
Kim, Brian [3 ,4 ]
Beck, Lisa A. [5 ]
Teixeira, Henrique D. [6 ,7 ]
Wu, Meijing [6 ,7 ]
Calimlim, Brian M. [6 ,7 ]
Thyssen, Jacob P. [8 ]
机构：
[1] Univ Hosp Munster, Dept Dermatol, Munster, Germany
[2] Univ Hosp Munster, Ctr Chron Pruritus, Munster, Germany
[3] Washington Univ, Sch Med, Dept Internal Med, Div Dermatol, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Ctr Study Itch & Sensory Disorders, St Louis, MO USA
[5] Univ Rochester, Dept Dermatol, Med Ctr, Rochester, NY 14627 USA
[6] AbbVie Inc, Clin Dev Hlth Econ & Outcomes Res, N Chicago, IL USA
[7] AbbVie Inc, Data & Stat Sci Res & Dev, N Chicago, IL USA
[8] Univ Copenhagen, Bispebjerg Hosp, Dept Dermatol & Venereol, Hellerup, Denmark
来源：
ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
PT26
引用
收藏
页码：60 / 61
页数：2
相关论文
共 50 条
  • [1] Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis from a phase 2b, randomized, controlled trial
    Guttman-Yassky, Emma
    Beck, Lisa A.
    Anderson, Jaclyn K.
    Hu, Xiaofei
    Gu, Yihua
    Teixeira, Henrique D.
    Silverberg, Jonathan I.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB294 - AB294
  • [2] Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial
    Guttman-Yassky, Emma
    Silverberg, Jonathan I.
    Thaci, Diamant
    Papp, Kim A.
    Staender, Sonja
    Beck, Lisa A.
    Kim, Brian S.
    Hu, Xiaofei
    Liu, Jianzhong
    Calimlim, Brian M.
    Vigna, Namita
    Crowley, Jameson T.
    Teixeira, Henrique D.
    Thyssen, Jacob P.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (12) : 2558 - 2568
  • [3] The patient-reported burden of atopic dermatitis and its association with itch: Observations from the upadacitinib phase 2b randomized, placebo-controlled trial in moderate to severe atopic dermatitis
    Silverberg, Jonathan I.
    Calimlim, Brian
    Teixeira, Henrique D.
    Wu, Meijing
    Simpson, Eric L.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB77 - AB77
  • [4] Time to Upadacitinib treatment response over 16 weeks for patients with atopic dermatitis from Phase 2b randomized, placebo-controlled trial
    Reich, Kristian
    Guttman-Yassky, Emma
    Hu, Xiaofei
    Calimlim, Brian
    Teixeira, Henrique
    de Bruin-Weller, Marjolein
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 18 - 19
  • [5] UPADACITINIB EFFECT ON PRURITUS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS; FROM A PHASE 2B RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Beck, L.
    Hong, C.
    Hu, X.
    Chen, S.
    Calimlim, B.
    Teixeira, H.
    Guttman-Yassky, E.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S21 - S21
  • [6] Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
    Gooderham, Melinda J.
    Girolomoni, Giampiero
    Moore, Julian O.
    Silverberg, Jonathan, I
    Bissonnette, Robert
    Forman, Seth
    Peeva, Elena
    Biswas, Pinaki
    Valdez, Hernan
    Chan, Gary
    [J]. DERMATOLOGY AND THERAPY, 2022, 12 (09) : 2077 - 2085
  • [7] Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
    Melinda J. Gooderham
    Giampiero Girolomoni
    Julian O. Moore
    Jonathan I. Silverberg
    Robert Bissonnette
    Seth Forman
    Elena Peeva
    Pinaki Biswas
    Hernan Valdez
    Gary Chan
    [J]. Dermatology and Therapy, 2022, 12 : 2077 - 2085
  • [8] Treatment withdrawal and retreatment with upadacitinib in patients with moderate-to-severe atopic dermatitis from a phase IIb, randomized, controlled trial
    Reich, K.
    Thaci, D.
    Papp, K.
    Anderson, J.
    Hu, X.
    Gu, Y.
    Teixeira, H.
    Guttman-Yassky, E.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E98 - E99
  • [9] Early response to upadacitinib in moderate-to-severe atopic dermatitis: Results from a phase 2b randomized, placebo-controlled trial
    Reich, K.
    Guttman-Yassky, E.
    Beck, L. A.
    Hu, X.
    Pangan, A. L.
    Teixeira, H. D.
    [J]. ALLERGY, 2018, 73 : 76 - 76
  • [10] Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses
    Mohamed, Mohamed-Eslam F.
    Gopalakrishnan, Sathej
    Teixeira, Henrique D.
    Othman, Ahmed A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (05): : 628 - 635
12345